

Universal Health Services Inc. (UHS)

NYSE; healthcare; SIC 8062, Services-General Medical & Surgical Hospitals, NEC; CIK 0000352915

Universal Health Services Inc. UHS; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 53.8; sampling error 2.5 points; lower is stronger
Rank	200 of 371
Profitability	C percentile 55.5
Solvency	C percentile 47.4
Growth and financing	C percentile 44.4
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$15.5B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: dilution, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 226 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$175.66 2026-10-08; market equity \$0
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Feb 21, 2024, B from Mar 21, 2025, B/C from Feb 21, 2026, C from Mar 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

Our principal business is owning and operating, through our subsidiaries, acute care hospitals and outpatient facilities and behavioral health care facilities. As of February 25, 2026, we owned and/or operated 375 inpatient facilities and 168 outpatient and other facilities located in 40 states, Washington, D.C., the United Kingdom and Puerto Rico. We have changed the method of our outpatient behavioral health care facility counts during the third quarter of 2025 and substantially all of the increase from prior periods is related

to that change in convention.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 55.5						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		13.3%	9.3%	37.0	74	2025-12-31
Accruals ratio		(2.5%)	(6.6%)	74.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 47.4						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		1.78x	1.82x	48.6	75	2025-12-31
Interest coverage		12.78x	(4.51x)	5.0	81	2025-12-31
Current ratio		1.05x	2.96x	88.4	839	2025-12-31
Growth and financing, sleeve percentile 44.4						
Revenue growth, three-year compound		9.0%	10.0%	52.9	415	2025-12-31
Free cash flow growth, three-year compound		48.0%	10.9%	13.7	96	2025-12-31
Reinvestment rate		(1.1%)	37.1%	69.9	104	2025-12-31
Asset growth, three years		4.8%	2.1%	41.3	704	2025-12-31
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 0

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
195	Aveanna Healthcare Holdings, Inc. (AVAH)	52.4	C	
196	Nexgel, Inc. (NXGL)	52.8	C	late filer

197	Nexgel, Inc. (NXGLW)	52.8	C late filer
198	Perrigo Co. plc (PRGO)	53.2	C
199	Sotera Health Co. (SHC)	53.5	C
200	Universal Health Services Inc. (UHS) <	53.8	C
201	Roivant Sciences Ltd. (ROIV)	54.1	C fortress balance sheet
202	Emergent BioSolutions Inc. (EBS)	54.3	C
203	Abbott Laboratories (ABT)	54.6	C
204	Teladoc Health, Inc. (TDOC)	54.9	C fortress balance sheet
205	Neuronetics, Inc. (STIM)	55.1	C

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.5%)	8.0%	33
Distance from 52-week high	(28.0%)	(31.4%)	55
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.39)	(0.14)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$138.8M
Operating cash flow, four quarters	\$1.8B
Months of runway	not finite
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$115.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$2.0B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$2.0B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$461.0M	2025-12-31	2026-02-25	10-K	0001193125-26-071676
4	total debt	us-gaap:LongTermDebt	\$4.8B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
5	book equity	us-gaap:StockholdersEquity	\$7.3B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$137.8M	2025-12-31	2026-02-25	10-K	0001193125-26-071676
7	total debt	us-gaap:LongTermDebt	\$4.5B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
8	book equity	us-gaap:StockholdersEquity	\$6.7B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$126.0M	2024-12-31	2026-02-25	10-K	0001193125-26-071676
10	net income	us-gaap:NetIncomeLoss	\$1.5B	2025-12-31	2026-02-25	10-K	0001193125-26-071676

11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.9B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
12	assets	us-gaap:Assets	\$15.5B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
13	assets	us-gaap:Assets	\$14.5B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
14	depreciation amortization	us-gaap:Depreciation	\$594.0M	2025-12-31	2026-02-25	10-K	0001193125-26-071676
15	interest expense	us-gaap:InterestExpense	\$156.1M	2025-12-31	2026-02-25	10-K	0001193125-26-071676
16	current assets	us-gaap:AssetsCurrent	\$3.4B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
17	current liabilities	us-gaap:LiabilitiesCurrent	\$3.2B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$17.4B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.8B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.3B	2023-12-31	2026-02-25	10-K	0001193125-26-071676
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.4B	2022-12-31	2025-02-26	10-K	0000950170-25-027785
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.0B	2025-12-31	2026-02-25	10-K	0001193125-26-071676
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.1B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$943.8M	2024-12-31	2026-02-25	10-K	0001193125-26-071676
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.3B	2023-12-31	2026-02-25	10-K	0001193125-26-071676
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$743.1M	2023-12-31	2026-02-25	10-K	0001193125-26-071676
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$996.0M	2022-12-31	2025-02-26	10-K	0000950170-25-027785
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$734.0M	2022-12-31	2025-02-26	10-K	0000950170-25-027785
29	current assets	us-gaap:AssetsCurrent	\$2.8B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
30	current liabilities	us-gaap:LiabilitiesCurrent	\$2.2B	2024-12-31	2026-02-25	10-K	0001193125-26-071676
31	assets	us-gaap:Assets	\$14.0B	2023-12-31	2025-02-26	10-K	0000950170-25-027785
32	assets	us-gaap:Assets	\$13.5B	2022-12-31	2024-02-27	10-K	0000950170-24-021175